A team of scientists at the Helmholtz Institute for RNA-based Infection Research (HIRI) in Würzburg and the University of Regensburg has unveiled insights into how HIV-1, the virus responsible ...

The device demonstrated a detection limit of 30 copies/mL of HIV RNA, a level comparable to traditional laboratory methods, with no cross-reactivity to hepatitis C virus (HCV). Clinical testing ...

Weight trajectories differed significantly among patients with HIV during the first year of ART, with no associations observed between weight gain and type of ART regimen.

It doesn't import its RNA genetic material ... capsid—basically the whole virus minus its outer membrane—through the nuclear pore in one piece. The HIV-1 capsid protein makes up most of ...

Despite the rebound, HIV RNA and DNA remained undetectable in blood cells derived from the donor, and HIV-specific T-cell responses and antibody levels did not increase. This suggests that the ...

Lenacapavir, however, is the first drug to disrupt the protective capsid layer surrounding HIV's genetic material (RNA), blocking the virus's ability to reproduce and be transmitted from person to ...

Researchers assessed epidemiologic trends of incident hepatitis C virus infection among patients with HIV infection engaged in care in the US.

Lenacapavir, however, is the first drug to disrupt the protective capsid layer surrounding HIV's genetic material (RNA), blocking the virus's ability to reproduce and be transmitted from person to ...